Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
about
The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equolDietary phytoestrogens inhibit experimental aneurysm formation in male mice.Isolation of a human intestinal bacterium capable of daidzein and genistein conversionIdentification of an enzyme system for daidzein-to-equol conversion in Slackia sp. strain NATTS.Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein.Towards microbial fermentation metabolites as markers for health benefits of prebiotics.Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine.Effect of isoflavones on cardiovascular health: low but not out either.O-desmethylangolensin inhibits the proliferation of human breast cancer MCF-7 cells by inducing apoptosis and promoting cell cycle arrest.Alternatives to animal experimentation for hormonal compounds researchAnalytical and compositional aspects of isoflavones in food and their biological effects.Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist.Antihyperglycemic effect of equol, a daidzein derivative, in cultured L6 myocytes and ob/ob mice.Effects of equol on multiple K+ channels stably expressed in HEK 293 cells.Androgen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: amelioration by daidzein.Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries.Identification of benzopyran-4-one derivatives (isoflavones) as positive modulators of GABA(A) receptors.
P2860
Q28087603-AF9682A6-C9D9-4832-9303-D623595E2AC7Q30405538-AF3E8CE3-CE9F-4020-B587-1802EFD997F6Q33399380-2F840401-1705-4015-8556-B8AA383ADC05Q34104652-33508887-A256-41B8-AE5F-D95D42612B8CQ34303495-34D97271-5C69-4B92-BC80-03492E57DDD6Q35686508-A3787D2A-1A11-431D-926D-0A3A35A4D09BQ36845014-54309EB0-881C-4B9D-AB46-B278A2F09F66Q36871500-A2F5539A-2A14-4467-8866-F3D237C8D6E2Q37325161-328FF84A-0AF3-4142-91AE-DE42CC3411ACQ37350782-6BF3DCB8-8AFD-4E67-AAA9-54F9E67AA072Q37602049-75AE51B1-8358-47B0-A59B-F2B8A9AD7D03Q37905857-448DCBFB-71C8-4494-A497-81362A836332Q38312561-49D2597D-7E0D-4537-85B2-19FBE2060564Q41498881-A0812175-45FB-432A-BC11-FBD9548D1DAAQ42714392-AA7415F0-9BFA-43AC-AD8C-365E2F67F594Q43198450-FD689106-2174-4957-A783-98A356FB8ABFQ48673559-186D5921-052F-4261-8B2E-57D0F2115385
P2860
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@en
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@nl
type
label
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@en
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@nl
prefLabel
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@en
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
@nl
P1476
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights
@en
P2093
Christopher G Sobey
Katherine A Jackman
P304
P356
10.2174/092986707782360178
P577
2007-01-01T00:00:00Z